Calmare Therapeutics Inc (CE) (CTTC) Quote

CTTC SEC registration revoked:

https://www.sec.gov/litigation/opinions/2023/34-97911.pdf

Well, I TOLD you so! Told you the company was a SCAM...told you Marineo was a con man and FRAUD...told you the stupid machine was nothing but pseudoscience but you wouldn't listen! Nothing in return but insults, rude remarks, ingratitude, etc, etc... Oh, well, maybe NEXT time you'll pay more ATTENTION!

How can 2000 shares trade at that price. Do you just give the seller a single M&M?

The joke must be:
How far did you have to chase the buyer in order to give him your shares?

Too bad about your losses. I took most of mine as write-offs again capital gains several years ago, but regret not having sold at decent gains many years before.

Never fall in love with a company or its story

Still here. At a loss for words after losing $$$.

Not sure what happened. Never previously observed this type of situation.

Is that a measurable share value or a round-off error because the systems cannot accept a value of "zero", much like not being able to divide by zero without getting massive computer crashes?

Does this signal the end? I would think so, if only because there may not be anyone left in this room, let alone at CTTC.

What happens to all those clinics and their patients and who services them when they need supplies or some serious tech support?

Personally, once powderbum left it became evident that all of the true-believers and Kool-Aid drinkers were gone or had finally given up on this firm.

Too bad the shareholders cannot lien Mir's home and sue him for the job he has done, but maybe, if his cash cow is gone, he loses his home anyway.

Does Brennan feel any remorse or was this either a major tax write-off or a chance to now grab all the assets for next-to-nothing and work out a deal with someone else, even the original inventor. Unfortunately, it may either be too late or the device really does very little good and has little value.

Final question: is there anyone left to respond to me?

New Low !! 0.000001

The reason the action was failure to file financial reports. They were given a couple of weeks to determine a mechanism to rectify. Haven’t heard how that is evolving.

Did they give a reason for this action? Why only two weeks and not, as you indicate, permanently?

For those still believing in CTTC, whoever they might be and wherever they might be (even Powderbum has silently slipped into the night), this must represent a slow and painful death by a thousand stings or maybe the old Chinese water torture.

I can only believe this latest action must be the result of a constant and consistent failure by Calmare to file any required paperwork or produce any of the documents they may have been asked for by the SEC. Given Mir's sterling performance as the CEO, is there anyone surprised?

I wonder whether any of the clinics using the device seek alternative ways for treatment or has the inventor come around to their doors and offered his newer device. I also wonder whether the Smithsonian might want a Calmare machine for their collection.

Finally, let me invite you to watch the following youtube video, albeit slightly abridged, but with subtitles.

"SECURITIES EXCHANGE ACT OF 1934 Release No. 92976 / September 14, 2021

The U.S. Securities and Exchange Commission announced the temporary suspension of trading
in the securities of the following issuer, commencing at 9:30 a.m. EDT on September 15, 2021
and terminating at 11:59 p.m. EDT on September 28, 2021:

Calmare Therapeutics Incorporated (CTTC)"

Now when will they finally make it PERMANENT?

This action should have been taken long ago. It appears they have not filed financial statements since Dec 2016, which is about the most impressive achievement that the CEO has accomplished since he took over.

What a farce! I feel very sorry for those who held their shares and even chose to accumulate more shares over the past decade. Many of those failed to demand that Brennan the Board Chair take any action and one can only believe he has always anticipated this event and saw CTTC as a tax loss opportunity or a chance to, somehow, take it privately.

It is unfortunate that the few efforts to wrestle the company away from the present Board and CEO failed miserably, although they might well have been trying to resurrect a dead horse and nothing might have saved the company.

While not being able to trade the stock does not signal the very end, one has to wonder what the various clinics still treating patients may now do, going forward. This has always been a mystery and I often wondered if spare parts are kept in Mir's basement in NJ (hopefully not flooded out) or elsewhere. Will those clinicians drift toward the inventor's version, if it exists and is any more viable?

BTW, given this kind of info, do the government agencies, assuming they read such stuff, have to avoid purchasing (if they do) and do they cancel any contract or grants? Of course, it has never been very clear that any of those programs or contracts ever existed aside from some "loaners" to the VA or military.

All those who have hung in as shareholders, as opposed to those like myself, that took their losses and became observers, should have seen the brightest and clearest "sell signal" over the past year or so when "powderbum", the single most optimistic cheerleader ceased to post either any of his upbeat messages (eventually far and few between) or his links regarding why opioids were very dangerous (his single most important and critical message theme). Once he left the scene, anyone with an ounce of good sense should have realized that the light may well have been switched off.

CTTC SEC Suspension for severely delinquent Financials:

https://www.sec.gov/litigation/suspensions/2021/34-92976.pdf

Order:

https://www.sec.gov/litigation/suspensions/2021/34-92976-o.pdf

Admin. Proceeding:

https://www.sec.gov/litigation/admin/2021/34-92977.pdf

Are they still in Business???

Anybody home?

What were sales in Q1?

Don’t know about the actual value of the federal contract. It would be easier to assess if we could see financial statements

How can we tell? Would like to see financial statements.

What is the value of the drive?

That was never clear other than being to download information from one Calmare device to another or to a computer?

How was this data downloaded or collected previously? Paper printout or by connecting a cable between devices?

How much demand is there for such transfer, i.e., when or why do you need this especially if you are a lone practitioner or a medical facility with only one Calmare?

Many questions and few answers.

Meantime, have their been results form this federal contract, i.e., real and substantial revenues?

The last sec filing that I saw announced a contract with the federal government. Will future RFPs include the specification of the drive?

The wording of what in the spec?

The need to have a device that can allow for transfer of data via a portable drive?

The need to have a device that been upgraded
within the past 10 years?

The need to have a manufacturer/vendor who has demonstrated financial viability including filing quarterly and annual reports in a timely manner

The need to have a manufacturer/vendor who's HQ is not in the basement of the CEO's home

The question on the table is the wording of federal contracts. Will this minor change be included in the specs?

It would appear, from reading, the entire description, that they patented a way of using, what they called a "memory stick" aka a "jump drive" that now costs about $15 for a 16GB drive (enough for all of the Calmare users ever.

There does not appear to be any indication that they have changed the algorithms at all. What they have added is a method of plugging in your memory stick and downloading whatever data it may have about you (or others) and then taking that stick over to another Calmare device and unloading or uploading your data to that machine.

I am not sure it is needed unless you are moving from one clinic to another and they cannot write your setting on an earlier version of a memory device that is eco-friendly, e.g., pad of paper. Maybe they have a way of keeping track of other data, but who knows.

I would have thought after so many years of experience, they might have upgraded the entire device, but this seems minimal and not an upgrade to justify anyone wanted to change devices.

Was this a low-ball effort to try to differentiate between this vaccumm-tube era device and the new device that the inventor has now patented and announced? If so, the dull thud is what the market thought

CTTC New Patent Also?



CTTC might also have a patent on a "new" version of the Calmare device. Patent was granted to Santanu Das (supposedly a CTTC director per SEC filing, but not reflected on website). Assignee of the patent is CTTC. Maybe there is a second generation device planned by CTTC--if CTTC plans anything anymore. Can't tell. Not sure whether this is still current info (from 2019).

It seemed inevitable that there would either have to be new technology to replace the creaky old vacuum tubs tech of the CTTC Calmare machine or the company would collapse and be overtaken by newer and better devices.

What we now see is that Marineo, having been spurned, snubbed, and tossed aside, has managed to go back to the lab, hire some high-end Milanese designers, engage some new tech manufacturers, and upgrade or tweak the machine. We do not know what adjustments he has made, but there have been enough clinical trials and patients for data to have been collected that could have guided his new device.

What now should be interesting, of course, is whether there will be a patent or marketing rights dispute should Calmare claim they should be marketing the device in the US and elsewhere, or whether they are shut out.

Furthermore, how will the various Calmare clinics react? Are they stuck either by contract or debt to Calmare and must continue with the machines they own, or can they choose to dump the older machines and opt for the ST-5A? Assuming it is not much different in overall operation, the learning curve may not be treacherous or long and, if the price is right, why not buy the latest and greatest. After all, most of us, unless we are antique car collectors, tend to hold their car for 6 years or so, and the Calmare machines are much older. They may also not have replacement parts since, as I recall, the Koreans are no longer making them and they may be scavenging parts from the many unsold units in warehouses (especially since Radio shack and Fry Electronics are gone)

I am assuming that the CEO and the Board Chair must have know this was coming, if not the CEO may now be walking around with a big brown wet spot on the backside of his pants. Shareholders might typically dump out of fear of a drop, but where can the price fall anyway? The only hope now is to convince day traders that Calmare is GameStop in Italian

NEWS PROVIDED BY
Delta International Services & Logistics s.r.l.
Feb 17, 2021, 09:00 ET
ROME, Feb. 17, 2021 /PRNewswire/ -- The next generation Scrambler Therapy® Technology ST-5A has received marketing approval from the FDA (K201458). This new device replaces the previous two generations known as "Calmare®" and "Scrambler Therapy® Technology MC-5A" respectively, which are no longer in production with DIS&L..

Indications for Use (MDR 745/2017)


Scrambler Therapy® device ST-5A (Made in Italy). Replaces the previous model MC-5A.
The specific indications for use are clinical results from scientific literature indexed and published in peer review scientific journals, based exclusively on this technology are:

Symptomatic relief of chronic opioid-resistant pain.
Symptomatic relief of chronic neuropathic and cancer pain.
In general, this device is indicated for all forms of severe chronic pain, specifically pain that does not respond to other pharmacological or non-pharmacological treatments, including opioids.

This third generation medical device is made entirely in Italy, where the scientific research that generated this technology originated. Among the most significant innovations are a modernized design, integrated compatibility dual power supply, quality guaranteed by the strict European Medical Device Regulation, and the stylistic and technological tradition of "Made in Italy".

About Delta International Service & Logistics

DIS&L is the agency created for the international development of Scrambler Therapy® Technology, and the selection of Scrambler Therapy Technology ST-5A Medical Device distributors in all international areas. DIS&L through its law firm is the only company authorized to sign international exclusive agreements, provide maintenance and client support for technical treatment training and other logistical needs.

www.st-team.eu

About Scrambler Therapy®

Scrambler Therapy® scientific research and development technology has been developed in Italy by Professor Giuseppe Marineo, who is the sole owner of its intellectual property rights. The official "Scrambler Therapy"® scientific and clinical information website is:

New Scrambler Therapy Technology ST-5A Medical Device released in the US by DIS&L, Rome, Italy. Replacing "Calmare" and Scrambler Therapy Technology MC-5A Medical Devices.

Read news release at PR Newswire

https://patientengagementhit.com/news/opioids-lead-to-worse-pain-management-poor-patient-health-outcomes

” The need to find alternative nondrug means of treating patients’ pain is paramount, especially during times of crisis. Clinicians need to be open to these complementary and alternative therapies and accept them as valid alternatives.

Of importance, it may increase calls for insurance companies to cover these treatments and for future providers to specialize in their administration. “That could really be a silver lining here. If clinicians are motivated to find someone in the community that employs biofeedback, relaxation or mindfulness meditation, patients may be able to lower or eliminate their need for controlled substance medications. That’s a big piece that’s missing,” Gudin told Pain Medicine News. “We know it works. We know if you get patients to think positively about their pain, they actually feel better. Everybody wants it, but not many know enough about it or are willing to pay for it.”

https://mail.google.com/mail/u/0/#inbox/WhctKJWQfjwcvBwVPBSptXHCWDsnlRDsnMcRHlvfKBQGMGQTllFMBjqWcHRTnZXscdTqfKG

I agree. But it may in the future.I'm not privy to any new research information.

Calmare is a wonderful product. I know it works!
My comment was intended to mean that this patient success will not impact share price.

Do you have any idea of progress on any clinical trials?

Thanks for the information. My experience has been that nothing is working that great and ofcourse doctors recommend pills. They do the same thing for all chronic pain. How is that working? Not very well. This particular patient had been to every reputable migraine clinic in the country and NOTHING but Calmare worked.

You might want to look at another company in the device space. ECOR is already labeled for migraine and has done clinical trials. Doctors prefer meds and another medication is on the clinical path to FDA approval.

Jan 19
New patient Shar adds her pin to our Calmare global map. Battling #arachnoiditis for 4 years, a severe #chronicpain disorder, her pain has reduced from a 9.5 to a 2.5 after two Calmare sessions. And we're not done yet. #neuropathy #Calmare #waronpain

This might be a break through. Look at this post on Facebook talking about Calmare:


Kathleen Hansen
It has saved our granddaughter who suffered immensely with chronic migraines!! Thank you Tom for introducing this machine to her????????

How big ia that market?

Migraine Statistics

By Editorial Team · November 30, 2010
SHARE

In the U.S., more than 38 million people have migraine disease, with some estimates suggesting that this number may be even higher, impacting as many as 50 million or more. Some migraine studies estimate that 12 percent of adults in the U.S. population have migraine, and 4 million have chronic migraine.1,2

Most individuals in the U.S. with migraine experience one to two migraine attacks per month, however, those with chronic migraine may have 15 migraine days, or more, per month. Approximately 9 out of every 10 people with migraine cannot function normally during an attack, and roughly one in five are disabled.2

The long march to oblivion

In looking at the share price for this past year, it is clear that we are now at less than a third of the January level with no foreseeable positive signs or any documented evidence that any change is coming.

Whether you take the shorter view (one year), a longer view (5 years), let alone a very long view (10 or more years), it is evident that CTTC is only heading downward and, like the afternoon sun, sinking in the west and soon to disappear from view.

I realize that some might argue that, much like every morning, the sun rises again, but what what works astronomically does not necessarily work in the world of commerce, business, or economics. Not every graph or trend is a sine curve with highs following lows. some are straight lines or even asymptotic. I suspect that CTT is the latter and has reached close to its lower limit, never getting to zero, but never to rise again. Sadly, there seems nobody with a gun or equivalent willing or able to put it out of its misery.

Best wishes for a happy new year

Thanks

0278T

PAIN MEDICINE NEWS

https://mail.google.com/mail/u/0/#inbox/WhctKJWJHdSfrVHSbSLPPFzBxVtfkCbXnKsKRxRQrZXkMHGSwfPhZvxBHHgGvlclVjMLbgg

https://www.eurekalert.org/pub_releases/2020-12/uowh-pwo122220.php

Lots of other questions. Publishing the required SEC filings might shed some light.

I occasionally look in on this board, if only out of curiosity to see whether anyone still cares other than powderbum. Even he, however, seems to have realized that nobody cares anymore and that, all of his shares (I suspect very many), may, if they still printed fancy certificates, might serve as wallpaper in his den.

At one time, this was a promising technology, but a combination of ineptitude on the part of the Board of Directors and their most recent choice of CEO, let alone greed on the parts of one notable prior CEO., has led to abject failure.

Private doctors and clinics (some closely allied with the firm) still offer the therapy and, obviously, some patients have done well, but for all of the many studies and reports from the researchers, the product has gone nowhere, even as they try to tout government contracts, that do not seem to stir up buying of the stock or sales and income. At some point in the near future, the hardware will just rust and the electronics and technology will become too obsolete to use anymore. I wonder, in all this about the following:
1) Where is the original inventor and what is he doing now?
2) Where is John Nano and what is he doing now?
3) Where are some of the CEO's that came after Nano or were around when he came back at a hefty price?
4) Where is the Chairman of the Board and does he still own lots of shares?
5) What do the other members of the Board do or think?
6) What happened to the ill-fated effort to wrest the company away from the present board and management?
7) What does the present CEO actually do and why is he paid for this, let alone where does that money come from?

You may add as many more questions as you like and also, provide answers if you have them

Is anyone Home ???

What is the reimbursement code for private insurance?

We are not covered by Medicare !!
How could that be?

The NO Pain Act This may be the key to Medicare covering Calmare: https://www.congress.gov/bill/116th-congress/house-bill/5172/text

GLOBAL PAIN RELIEF THERAPY MARKET (COVID 19 UPDATE) ADMIRABLE GROWTH ANALYSIS BY PRODUCT TYPE, APPLICATIONS, REGIONAL OUTLOOK, TECHNOLOGY, OPPORTUNITY 2020 – 2027
Posted On: October 1, 2020 Posted By: Sopan Comments: 0
DBMR has added a new report titled Global Pain Relief Therapy Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from consistent sources such as websites, annual reports of the companies, and journals which is then checked and validated by the market experts. Global Pain Relief Therapy Market report has been structured with transparent research studies which makes it of supreme quality. By exactly understanding customer requirement, one or more methods are used to construct this finest market research report. The report provides with CAGR value fluctuation during the forecast period of 2020 – 2027 for the market.

Global Pain Relief Therapy Market is expected to rise from its initial estimated value of USD 1117.61 billion in 2016 to an estimated value of USD 1,849.63 billion by 2026, registering a CAGR of 6.5%in the forecast period of 2016-2026. Increasing investment on R&D is driving the growth of this market.

Download PDF Sample Copy of Report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-pain-relief-therapy-market

Key Market Competitors: Global Pain Relief Therapy Market

Some of the major players operating in global pain relief therapy market are Johnson & Johnson Services, Inc., Eli Lilly & Company, Merck & Co. Inc., Pfizer, Inc., Abbott, F. Hoffmann La Roche Ltd., DJO, LLC, Breg, Inc., Beiersdorf AG, Medline Industries, Inc., 3M, Sanofi, ROHTO Pharmaceutical Co., Ltd., Össur Americas, Hisamitsu Pharmaceutical Co., Inc., Calmar Pain Relief, LLC, UltraCare PRO, Polar Products Inc., Agm Overseas, Stimwave LLC, Neurometrix, Niagara, Calmare Therapeutics Incorporated, Iskra Medical d.o.o., THERALASE Technologies Inc., Sombra Professional Therapy Products, Good Health Naturally, Endo Pharmaceuticals Inc., BioElectronics Corporation, HYH, Danaher, ALLERGAN, Purdue Pharma among others

Report Segmentation

Global Pain Relief Therapy Market By Products (Prescription based products, OTC-based products {Pharmaceuticals, Medical Devices}), Mode of Purchase (Over-The-Counter, Prescribed), Application (Musculoskeletal Disorder, Sport Medicine, Post-operative, Post-trauma, Physical Therapy), End-User (Hospitals, Clinics, Ambulatory Centers, Physiotherapy Centers, Homecare Settings), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026

Market Definition: Global Pain Relief Therapy Market

Pain is complex and its medication is of various types, natural pain may occur due to natural lifestyle changes, pain may occur due to several reasons eg; Injuries, chronic diseases.

Pain is an intensely unpleasant sensory nervous system’s mechanism to alert the brain that action must be taken as quickly as possible to protect the body from various symptoms.

Market Drivers

The advancements of large untapped markets, drug development in the developing economies are anticipated to provide new avenues for the industry growth in the near future.
Due to growing awareness about potential implications of prolonged use of pain treatment drugs, including reduced efficacy, risk of addiction and side effects is going to drive the market growth
Market Restraints

Potential restraints of the global pain relief market are skin irritation, burning sensation and allergic reactions due to over usage of pain relievers.
Competitive Analysis:

Global pain relief therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of pain relief therapy market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Benefits

The study provides an in-depth analysis of the Pain Relief Therapy market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the predominant Pain Relief Therapy market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Pain Relief Therapy market.
The Global Pain Relief Therapy Market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of pain relief therapy market for global, Europe, North America, Asia Pacific and South America.

Inquire Regarding This Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pain-relief-therapy-market

I'm waiting and watching just like the rest of you. Stock is acting well. I saw a 700,000 bid in the stock today.

powderbum may know.

How do we know September revenues?

No revenues in September...

Tick

Tok

I'm cautiously watching to see if we get some gov. revenues before the end of Sept. and 2.7 million by the end of the year as projected. If those numbers come to pass than those future expectations become more realistic. Did you notice we had 1.2 million in revs in 2019? I think that was accurate. So let's see what happens. If he's right with his projections we should have a $20 plus stock in two years. From my lips to God's ears.

Super optimistic numbers, but...............

today, at 1:00pm EDT, Conrad presented a 16 minute PowerPoint presentation regarding Calmare. Rather than recap the presentation. I recommend you log in, register to be allowed to hear-see the presentation and form your own opinions

https://ld500.ldmicro.com/


Let me add that it is curious that:
1) powderbum has made no comments regarding what was "announced" or revealed
2) the company itself has never issues any press releases regarding any of the information or news
3) the company has not issues and quarterly reports or other fillings in forever
4)how do they expect to get interest or action when most potential share purchasers cannot get any brokerages to allow them to purchase the stock given lack of filings

It would be interesting to hear or read comments from anyone still on this Message Board if only as a voyeur

BC/BS in Michigan lost an appeal recently for not paying for Calmare. The Michigan Dept. of Insurance ruled the peer reviewed literature over the past 8 to 10 years supports positive study results on a variety of pain management types. This device is more likely than not to be better than the current standard of care.